Neumora Therapeutics (NASDAQ:NMRA) Stock Price Up 5.2%

Neumora Therapeutics, Inc. (NASDAQ:NMRA) traded up 5.2% during mid-day trading on Wednesday . The stock traded as high as $12.43 and last traded at $12.34. 189,205 shares changed hands during trading, a decline of 68% from the average session volume of 596,284 shares. The stock had previously closed at $11.73.

Analyst Ratings Changes

NMRA has been the subject of several research reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $29.00 target price on shares of Neumora Therapeutics in a research report on Wednesday, September 4th. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Neumora Therapeutics in a report on Thursday, September 12th. Finally, Mizuho started coverage on shares of Neumora Therapeutics in a research note on Monday, July 8th. They set an “outperform” rating and a $20.00 target price for the company. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $22.11.

Neumora Therapeutics Trading Up 6.1 %

The firm’s fifty day moving average price is $11.65 and its 200-day moving average price is $11.46.

Neumora Therapeutics (NASDAQ:NMRA) last posted its earnings results on Tuesday, August 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.37). Sell-side analysts expect that Neumora Therapeutics, Inc. will post -1.51 EPS for the current year.

Insider Transactions at Neumora Therapeutics

In related news, CFO Joshua Pinto sold 31,642 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $11.78, for a total value of $372,742.76. Following the sale, the chief financial officer now directly owns 154,658 shares in the company, valued at approximately $1,821,871.24. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 26.40% of the company’s stock.

Hedge Funds Weigh In On Neumora Therapeutics

Several large investors have recently bought and sold shares of the stock. Amalgamated Bank bought a new position in shares of Neumora Therapeutics in the fourth quarter valued at approximately $29,000. Quarry LP bought a new position in Neumora Therapeutics during the 2nd quarter valued at $98,000. SkyOak Wealth LLC acquired a new position in shares of Neumora Therapeutics during the 2nd quarter valued at $147,000. Principal Financial Group Inc. bought a new stake in shares of Neumora Therapeutics in the 2nd quarter worth $166,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Neumora Therapeutics in the second quarter valued at $566,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.